Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present FibroGen, Inc. (NASDAQ: FGEN).

Full DD Report for FGEN

You must become a subscriber to view this report.


Recent News from (NASDAQ: FGEN)

Institutional Top Ideas Series: Opaleye Management
In the last entry of this series, we took a look at top ideas from Ra Capital Management, the best performing fund we´ve come across so far with heavily concentrated positions in their top ideas. Going forward, I hope to continue to delve into the portfolios of successful hedge funds ...
Source: SeekingAlpha
Date: May, 17 2018 01:52
Biotechs perk up ahead of ASCO abstract drop
The SPDR S&P Biotech ETF ( XBI +1.1% ) is up  1%  as investors ramp up buying ahead of the abstract drop for the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 1 - 5. More news on: SPDR Biotech ETF, Celgene Corporation, bluebird bio, Inc., He...
Source: SeekingAlpha
Date: May, 16 2018 12:56
FibroGen's (FGEN) CEO Tom Neff on Q1 2018 Results - Earnings Call Transcript
FibroGen (FGEN) Q1 2018 Earnings Conference Call May 09, 2018 05:00 PM ET Executives Karen Bergman - VP of IR and Corporate Communications Tom Neff - CEO Seth Porter - VP of Fibrosis Therapeutics Peony Yu - Chief Medical Officer Pat Cotroneo - CFO Elias Kouchakji - SVP, Cli...
Source: SeekingAlpha
Date: May, 09 2018 22:38
FibroGen beats by $0.01, beats on revenue
FibroGen (NASDAQ: FGEN ): Q1 EPS of -$0.50 beats by $0.01 . More news on: FibroGen, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 09 2018 16:26
FibroGen Reports First Quarter 2018 Financial Results
Pamrevlumab Data to be Presented at ATS 2018 and ASCO 2018 Roxadustat U.S. Phase 3 Clinical Studies on Track to Readout in Fourth Quarter 2018 Conference Call Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time SAN FRANCISCO, May 09, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (N...
Source: GlobeNewswire
Date: May, 09 2018 16:02
Notable earnings after Wednesday's close
AG , ALB , AMPH , ANGI , ATUS , AYX , BLDR , BOLD , BREW , COLL , CPA , CTL , CVNA , DAR , DNB , EEP , ELF , ENV , ETE , ETP , EVH , FG , FGEN , FNGN , FNV , FOXA , FSM , FTI , FTK , GDOT , GKOS , HLI , IAC , ICUI , INFN , MBI , MELI , MRAM , MTRX , N...
Source: SeekingAlpha
Date: May, 08 2018 17:35
FibroGen to Report First Quarter 2018 Financial Results on Wednesday, May 9, 2018
SAN FRANCISCO, May 02, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that it will report first quarter 2018 financial results on Wednesday, May 9, 2018, after market close, and will host a conference call to discuss financi...
Source: GlobeNewswire
Date: May, 02 2018 07:00
Consolidated Research: 2018 Summary Expectations for MGM Growth Properties, Reinsurance Group of America, Cincinnati Bell, GAIN Capital, FibroGen, and First Hawaiian - Fundamental Analysis, Key Performance Indications
NEW YORK, April 27, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of MGM Growth Properties LLC (NYSE:MGP), Reinsurance Group of America, Inco...
Source: GlobeNewswire
Date: April, 27 2018 07:45
Wired News - FDA Granted Fast Track Designation to FibroGen's Pamrevlumab for Locally Advanced Unresectable Pancreatic Cancer
Stock Monitor: G1 Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 05, 2018 / Active-Investors.com has just released a free research report on FibroGen, Inc. (NASDAQ: FGEN ). If you want access to this report all you need to do is sign up now by clicking the follo...
Source: ACCESSWIRE IA
Date: March, 05 2018 07:40
3 Things In Biotech, March 3, 2018: FibroGen's Fast, INSYS Progresses, Idera Moves
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Fib...
Source: SeekingAlpha
Date: March, 04 2018 10:34

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1752.2051.3052.4051.15589,481
2017-02-0222.4023.2523.5022.2844500,970
2017-02-0122.7022.6522.8522.30393,182
2017-01-3121.8522.6522.7521.05986,552
2017-01-3024.5021.8024.7021.551,421,437

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1598,852136,97372.1690Short
2018-08-1471,014112,05763.3731Short
2018-08-1373,027115,44363.2581Short
2018-08-1027,29356,33148.4511Short
2018-08-0976,267114,79366.4387Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on FGEN.


About FibroGen, Inc. (NASDAQ: FGEN)

Logo for FibroGen, Inc. (NASDAQ: FGEN)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: FGEN)

      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 09 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 09 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 24 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 24 2018
      Amendment to a previously filed Form 4
      Filing Type: 4/AFiling Source: edgar
      Filing Date: April, 13 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 01 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: February, 27 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: February, 27 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 23 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: February, 16 2018

       

       


      Daily Technical Chart for (NASDAQ: FGEN)

      Daily Technical Chart for (NASDAQ: FGEN)


      Stay tuned for daily updates and more on (NASDAQ: FGEN)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: FGEN)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in FGEN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of FGEN and does not buy, sell, or trade any shares of FGEN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/